Blood Cancer Talks

Episode 24. ASCO/EHA 2023 Special: Updates on CAR T-cell Therapy in Myeloma

Jun 17, 2023
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 6min
2
The Differences Between CARMA 3 and CARTUT4
05:43 • 2min
3
The Differences Between CARTUT4 and DARA-KIDI
07:33 • 2min
4
The Top Line Results for Progression Free Survival With Silticell
09:21 • 3min
5
The Importance of Comparative Efficacy in Early Relapse Patients
11:54 • 5min
6
The Effects of Carti Cell Therapy on Toxicity
17:15 • 2min
7
The Non-ICANN's Neurotoxicity With Cilta Cell
18:45 • 4min
8
The Signal of Second Primary Malignancies in Parkinson's Disease
22:26 • 2min
9
The Safety and Effectiveness of a Dual-Card, a BCMA and CD19 Card, Followed by Emmett Maintenance in Patients With Early Relapse
24:37 • 4min
10
GPR-C5D-CARTY: A Next-Line Therapy for Low-Level Disease
29:03 • 2min
11
GPRC5D and BCMA Cartesal Therapy: A Comparison
31:15 • 4min
12
Cerebellar Toxicity in GPRC 5D CAR-T
35:39 • 3min
13
The Disadvantages of Loss of GPRC-5D Expression
38:54 • 2min
14
Aloe 715: A Phase 1 Universal Trial
41:06 • 3min
15
The Importance of Prophylaxis in CAR T Patients
43:45 • 4min